Evidence map›Paper›PMID 35590084›Full record

ArticleCell and tissue banking2022

Comparative study of mouse adipose- and bone marrow mesenchymal stem cells in diabetic model with critical limb ischemia.

Seyedeh-Leili Asadi-Yousefabad, Pegah Nammian, Mohammad Hasan Sheikhha, Seyed Mohammad Bagher Tabei, Sajad Daneshi, Habib Nikukar, Marzieh Lotfi, Vahid Razban

Abstract read
PubMed Publisher
In one paragraph

Article in Cell and tissue banking, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Seyedeh-Leili Asadi-YousefabadDepartment of Molecular Medicine, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Pegah NammianDepartment of Molecular Medicine, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.
Mohammad Hasan SheikhhaBiotechnology Research Center, International Campus, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. sheikhha@yahoo.com.
Seyed Mohammad Bagher TabeiDepartment of Medical Genetics, School of Medical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
Sajad DaneshiStem Cells Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Habib NikukarMedical Nanotechnology and Tissue Engineering Research Center, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Marzieh LotfiDepartment of Medical Genetics, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Vahid RazbanDepartment of Molecular Medicine, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran. razban_vahid@yahoo.com.
Shahid Sadoughi University of Medical Sciences and Health Services · IRShiraz University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this research is to compare the capabilities of Adipose tissue mesenchymal stem cells (AT-MSCs) and bone marrow mesenchymal stem cells (BM-MSCs) in the treatment of diabetic male mice with CLI model. Supernatants were collected from C57BL/6 mice isolated AT-MSCs and BM-MSCs, afterward their effects on human umbilical vein endothelial (HUVEC) migration potential were evaluated. Diabetes mellitus type 1 was induced by streptozotocin injection. Diabetic mice with CLI model were divided into three groups and injected with AT-MSCs, BM-MSCs, or PBS then the efficacy of them was assessed. Survival of MSCs was analysed by SRY-specific gene. The conditioned medium of AT-MSCs and BM-MSCs stimulated HUVECs migration and the donor cells were detected till 21 day in two groups. BM-MSCs and AT-MSCs improved significantly functional recovery and ischemia damage. Neovascularization in ischemic muscle was significantly higher in mice treated with AT-MSCs and BM-MSCs and they improved muscle regeneration. In vivo and in vitro findings show that AT-MSCs and BM-MSCs transplantation could be proposed as a promising therapy to promote angiogenesis and muscle regeneration through secretion of proangiogenic factors, cytokines and growth factors in diabetic mice with CLI model wherein blood supply is insufficient and disrupted.

Indexed as

Diabetes Mellitus, ExperimentalMesenchymal Stem CellsMesenchymal Stem Cell TransplantationAdipose TissueAnimalsChronic Limb-Threatening IschemiaHumansIschemiaMaleMiceMice, Inbred C57BLNeovascularization, PhysiologicAdipose tissue-mesenchymal stem cellsAngiogenesisBone marrow-mesenchymal stem cellsCritical limb ischemiaDiabetes mellitus

Identifiers

PMID35590084
OpenAlexW4280605746

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.